Annexon to present vonaprument geographic atrophy data at Retina Society Meeting. Key Takeaways * Two Retina Society presentations will examine phase 2 vision outcomes and phase 3 baseline characteristics for vonaprument in geographic atrophy * The ongoing 659-patient ARCHER II trial uses confirmed BCVA loss of at least 15 letters as its primary endpoint, with assessments through months 15 and 24 * Annexon expects the month 15 primary analysis from ARCHER II in the fourth quarter of 2026 Annexon announced that investigators will deliver two oral presentations evaluating vonaprument in geographic atrophy (GA) at The Retina Society 59th Annual Scientific Meeting, being held September 23-26, 2026, in Los Angeles. The presentations will focus on findings from the phase 2 ARCHER study and baseline characteristics of participants enrolled in the ongoing phase 3 ARCHER II trial. According to Annexon, the analyses support the clinical development strategy for vonaprument as a potential vision-protecting treatment for patients with GA secondary to dry age-related macular degeneration (AMD). Vonaprument, formerly known as ANX007, is an investigational antigen-binding fragment designed to selectively inhibit C1q, the initiating molecule of the classical complement pathway. The intravitreally administered candidate is intended to protect photoreceptors and retinal function by blocking C1q and the classical complement pathway while leaving the lectin and alternative complement pathways intact. Ashkan Abbey, MD, of Texas Retina Associates, will present "Baseline Characteristics of Participants in the Phase 3 ARCHER II Trial in Dry AMD With GA" on September 25 at 9:10 am PT. Annexon said the presentation will examine the replication of key baseline clinical characteristics between participants in the Phase 2 ARCHER and Phase 3 ARCHER II studies. Maintaining similar characteristics between the study populations is part of the company's strategy for determining whether the vision findings observed in the earlier trial can be confirmed in a larger Phase 3 population. A second presentation, scheduled for 9:13 am PT on September 25, will examine vision outcomes among ARCHER participants with subfoveal retinal pigment epithelium (RPE) lesions. Mark Barakat, MD, FASRS, of Retina Macula Institute of Arizona, will present the post hoc analysis. The completed Phase 2 ARCHER trial (NCT04656561) evaluated vonaprument in a broad population of patients with GA. Annexon reported that treatment demonstrated protection of visual function and ellipsoid zone retinal structure across multiple measures, including time- and dose-dependent effects on confirmed loss of at least 15 letters of best-corrected visual acuity (BCVA). According to the company, vonaprument was generally well tolerated through month 12, with no increase in choroidal neovascularization rates compared with sham and no reported retinal vasculitis events. ARCHER II (NCT06510816) is a global phase 3 study enrolling 659 patients. The trial was designed to evaluate whether the findings from ARCHER can be replicated, with confirmed BCVA loss of at least 15 letters serving as the primary endpoint through months 15 and 24. Annexon said the month 15 primary analysis is expected in the fourth quarter of 2026. The company has established a registration pathway with US and European regulators, and the single ARCHER II protocol is also designed to permit analysis as 2 substudies after the primary endpoint is met. Vonaprument has received Fast Track designation from the FDA and Priority Medicines designation from the European Medicines Agency for GA.

Annexon Biosciences has appointed Mark S. Blumenkranz, a renowned retinal surgeon and biotechnology entrepreneur, to its board of directors. Blumenkranz brings over four decades of clinical, scientific and corporate leadership experience in retinal disease. Blumenkranz is the H.J. Smead Professor Emeritus of Ophthalmology at Stanford University School of Medicine and co-director of Stanford's Ophthalmic Innovation Program. He has co-founded and led numerous ophthalmic companies through development and acquisition, including Adverum Biotechnologies, Optimedica Corporation, Oculeve, and Kedalion Therapeutics. The Brisbane-based biopharmaceutical company is advancing two late-stage clinical programmes, including vonaprument for geographic atrophy. Muneer Satter is stepping down from the board after more than 11 years of service.

Annexon secures up to $200 million credit facility to support global commercialization plans. Key Takeaways * Annexon has secured a strategic credit facility with Oxford Finance providing access to up to $200 million in non-dilutive financing * Annexon said the financing will support commercialization planning and strengthen its financial position as its lead candidates, vonaprument and tanruprubart, advance toward potential registration Annexon has entered into a strategic credit facility agreement with Oxford Finance that provides access to up to $200 million in non-dilutive financing as the company advances two late-stage neuroinflammatory disease programs toward potential commercialization. Under the terms of the agreement, Annexon received an initial $50 million at closing. An additional $100 million will become available upon the achievement of specified milestones related to the company's registrational programs for vonaprument and tanruprubart, while the remaining $50 million is subject to lender approval. "This strategic facility enhances our financial and operational capabilities as we prepare for the potential global commercialization of vonaprument and tanruprubart, which combined have the potential to reach millions of patients worldwide," said Douglas Love, president and chief executive officer of Annexon. "Access to this non-dilutive capital further diversifies our capital structure, strengthens our balance sheet, and accelerates our near and long-term growth strategy." Annexon is developing targeted immunotherapies for neuroinflammatory diseases, with vonaprument and tanruprubart representing its lead clinical-stage programs. In January 2026, Annexon submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for tanruprubart for the treatment of Guillain-Barré syndrome (GBS). Annexon is the developer of vonaprument, which is in phase 3 development for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA). Vonaprument is a first-in-kind, non-pegylated antigen-binding fragment (Fab) designed to block C1q locally in the eye with an intravitreal formulation.